ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm investigating Rocket Pharmaceuticals for potential securities fraud related to undisclosed clinical trial protocol changes and serious adverse events in RP-A501 study, which led to a 37% stock price drop.

10/23/2025, 6:03 PM • GlobeNewswire

DEADLINE ALERT for RCKT, DDD, TEM, RDDT: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law firm alerts investors about potential securities fraud class action lawsuits for four companies, alleging misleading statements and undisclosed risks during specific class periods in 2024-2025.

08/11/2025, 12:00 PM • GlobeNewswire

RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT

Rosen Law Firm alerts Rocket Pharmaceuticals investors about a securities class action lawsuit alleging false statements regarding the effectiveness and safety of drug candidate RP-A501, with an important deadline on August 11, 2025.

08/10/2025, 11:38 AM • GlobeNewswire

Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Law Offices of Frank R. Cruz alerts investors about an upcoming August 11, 2025 deadline to participate in a securities fraud class action lawsuit against Rocket Pharmaceuticals following an FDA clinical hold on a Danon disease treatment trial after a patient's death.

08/08/2025, 12:38 PM • Benzinga

MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Rocket Pharmaceuticals faces a class action lawsuit alleging misleading statements about its Phase 2 clinical trial for RP-A501, with claims of concealing serious adverse events including patient death, which led to an FDA clinical hold and stock price decline.

08/07/2025, 7:45 PM • GlobeNewswire

Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Rocket Pharmaceuticals faces a class action lawsuit after disclosing an FDA clinical hold on its Danon disease treatment trial following a patient's death, causing significant stock price decline.

08/07/2025, 2:32 PM • GlobeNewswire

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Rocket Pharmaceuticals after the FDA placed a clinical hold on its RP-A501 Phase 2 pivotal study following a patient's death, causing the stock price to drop 37% in one trading day.

08/06/2025, 4:00 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

Pomerantz Law Firm filed a class action lawsuit against Rocket Pharmaceuticals after a patient death in a Phase 2 gene therapy trial, causing the stock to drop 62.84%.

08/05/2025, 10:00 AM • GlobeNewswire

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman

Rocket Pharmaceuticals faces a securities class action lawsuit after the FDA placed a clinical hold on its Phase 2 trial for RP-A501, a gene therapy for Danon disease, causing its stock to drop over 60% on May 27, 2025.

08/04/2025, 2:49 PM • GlobeNewswire

מועד אחרון חשוב לתביעה נגד RCKT: רוזן, משרד ארצי מוביל, מעודד משקיעים ב- Rocket Pharmaceuticals, Inc עם הפסדים של יותר מ-100 אלף דולר להבטיח ייעוץ לפני המועד האחרון החשוב של 11 באוגוסט בתביעה ייצוגית בניירות ערך - RCKT

Rosen Law Firm alerts Rocket Pharmaceuticals investors about a securities class action lawsuit alleging false statements about clinical trial effectiveness and safety of drug RP-A501, with an important filing deadline on August 11, 2025.

08/02/2025, 1:12 AM • GlobeNewswire

RCKT IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT

Rosen Law Firm is investigating potential securities claims for Rocket Pharmaceuticals investors who purchased securities between September 17, 2024 and May 26, 2025, alleging false statements about drug effectiveness and safety.

08/01/2025, 5:55 PM • GlobeNewswire

Rocket Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 11, 2025 Deadline to file Lead Plaintiff Motion.

Rocket Pharmaceuticals faces a class action lawsuit alleging misleading statements about its Phase 2 trial for Danon disease treatment, with claims of undisclosed serious adverse events and protocol changes leading to an FDA clinical hold.

08/01/2025, 3:58 PM • GlobeNewswire

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

Rosen Law Firm is pursuing a securities class action lawsuit against Rocket Pharmaceuticals for allegedly making false and misleading statements about the effectiveness and safety of its drug RP-A501 during the period of September 17, 2024 to May 26, 2025.

07/28/2025, 2:45 PM • GlobeNewswire

DEADLINE ALERT: Holzer & Holzer, LLC Reminds Investors of August 8, 2025 Lead Plaintiff Deadline in the Vestis Corporation (VSTS) Class Action – Investors With Significant Losses Encouraged to Contact the Firm

Multiple shareholder class action lawsuits have been filed against technology and pharmaceutical companies, alleging false or misleading statements about business growth and performance.

07/28/2025, 12:47 PM • GlobeNewswire

DEADLINE ALERT: Holzer & Holzer, LLC Reminds Investors of August 11, 2025 Lead Plaintiff Deadline in the Rocket Pharmaceuticals, Inc. (RCKT) Class Action – Investors With Significant Losses Encouraged to Contact the Firm

A class action lawsuit has been filed against Rocket Pharmaceuticals alleging false statements and inadequate disclosure of serious adverse events, including participant deaths, during a study period from February 27 to May 26, 2025.

07/28/2025, 12:44 PM • GlobeNewswire